Napp has launched two new strengths of Targinact (oxycodone/naloxone). The 5mg/2.5mg and 40mg/20mg tablets provide greater dosing flexibility.
The starting dose remains 10mg/5mg, but the new lower-strength tablet allows a more gradual and individually tailored approach to dose titration. The new higher-strength preparation reduces tablet burden for patients requiring the maximum dose.
Furthermore, Targinact is now licensed for use at doses up to a maximum of 80mg oxycodone hydrochloride/40mg naloxone hydrochloride daily.
Further information: Napp